New antibiotic JKN2501 enters first human tests
NCT ID NCT07207291
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests the safety and tolerability of a new antibiotic called JKN2501 in 66 healthy adults in China. Participants receive either the drug or a placebo by IV infusion, and researchers monitor for side effects and how the drug moves through the body. The goal is to see if it is safe enough to study further for treating bacterial infections like urinary tract, abdominal, and respiratory infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JKN2501 (an experimental antibiotic given by IV infusion)
- What this could lead to
- If safe, this could lead to a new antibiotic for bacterial infections that are hard to treat.
- What could go wrong
- This is a very early Phase 1 trial in only 66 healthy people, so it is not yet tested in patients. The drug may cause side effects or fail in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Third hospital of Changsha
RECRUITINGChangsha, Hunan, 410035, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A gentle touch against coughs and colds: could manual therapy shorten respiratory illness?
- Could a simple blood test curb antibiotic overuse in sick kids?
- New drug CTX-187 takes aim at stubborn bacterial infections
- Can better school toilets and peer support boost girls' health and grades? a madagascar trial aims to find out.
- Blood markers may reveal who is at risk from severe abdominal infections
- Can smarter antibiotic choices curb superbugs in liver disease?